H19-Promoter-Targeted Therapy Combined with Gemcitabine in the Treatment of Pancreatic Cancer

Pancreatic cancer is the eighth cancer leading cause of cancer-related death in the world and has a 5-year survival rate of 1–4% only. Gemcitabine is a first line agent for advanced pancreatic therapy; however, its efficacy is limited by its poor intracellular metabolism and chemoresistance. Studies...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Sorin, Vladimir, Ohana, Patricia, Gallula, Jennifer, Birman, Tatiana, Matouk, Imad, Hubert, Ayala, Gilon, Michal, Hochberg, Avraham, Czerniak, Abraham
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: International Scholarly Research Network 2012
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3371723/
https://ncbi.nlm.nih.gov/pubmed/22701803
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5402/2012/351750
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak